title: Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
abstract: Multiple Sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating disorder of the central nervous system with a heterogeneous clinical presentation and pathology in which activated lymphocytes play an important role in mediating tissue damage. Until recently, all first line therapies for MS were injectable. Several oral medications have been studied for preventative treatment of MS. Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analog that has been used for the treatment of several hematologic neoplasms, with a unique lymphcytotoxic mechanism of action. Cladribine has been investigated as treatment of MS for more than 15 years. A recent placebo-controlled, double-blind study of cladribine, CLARITY, showed decreased relapse rates, risk of disability progression and MRI measures of disease activity at 96 weeks. Cladribine's strengths included high efficacy and convenient, biannual oral dosing. However, concerns about safety prevented the FDA from approving cladribine in 2011. Thus, use of cladribine for treatment of relapsing and remitting multiple sclerosis will remain off-label.
authors: Department of Neurology, University of Colorado, Denver, CO, USA.
authors: Teri L
authors: TL
authors: Schreiner
authors: Augusto
authors: A
authors: Miravalle
keywords: BG12; EDSS; Interferon beta 1a (Avonex); Interferon beta 1a (Rebif); Interferon beta 1b (Betaseron); Laquinimod; MRI; Teriflunomide; cladribine; clinical trials; disability progression; fingolimod (Gilenya); glatiramer acetate (Copaxone); methylprednisolone; mitoxantrone (Novantrone); multiple sclerosis; natalizumab (Tysabri); progressive; relapse rate; relapsing and remitting; treatment
references: Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35
references: 21242742
references: Acta Neuropathol. 2011 Aug;122(2):155-70
references: 21626034
references: Curr Opin Investig Drugs. 2001 Dec;2(12):1751-6
references: 11892941
references: Eur J Neurol. 2009 Mar;16(3):409-12
references: 19175384
references: Lancet. 1992 Oct 17;340(8825):952-6
references: 1357355
references: N Engl J Med. 2010 Feb 4;362(5):402-15
references: 20089954
references: Eur J Neurol. 2007 Jun;14(6):686-9
references: 17539951
references: Lancet. 1994 Jul 2;344(8914):9-13
references: 7912347
references: Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1716-20
references: 8643695
references: Leuk Lymphoma. 2004 Jan;45(1):187-8
references: 15061219
references: Ann Neurol. 1996 Mar;39(3):285-94
references: 8602746
references: Arch Neurol. 2011 Jul;68(7):870-8
references: 21403003
references: Lancet. 1994 Aug 20;344(8921):538
references: 7980785
references: J Neuroimmunol. 2006 Nov;180(1-2):3-8
references: 16934338
references: Neurology. 1993 Apr;43(4):655-61
references: 8469318
references: J Neurol. 2010 Feb;257(2):163-70
references: 19921304
references: Lancet. 2009 Oct 31;374(9700):1503-11
references: 19815268
references: Ann Neurol. 2010 Sep;68(3):295-303
references: 20737510
references: Lancet. 2001 May 19;357(9268):1576-82
references: 11377645
references: Neurology. 2006 Oct 10;67(7):1242-9
references: 16914693
references: N Engl J Med. 2006 Mar 2;354(9):924-33
references: 16510746
references: Ann Neurol. 2011 Feb;69(2):292-302
references: 21387374
references: Proc Assoc Am Physicians. 1999 Jan-Feb;111(1):35-44
references: 9893155
references: Clin Immunol. 2012 Jan;142(1):38-43
references: 21450529
references: N Engl J Med. 2010 Feb 4;362(5):416-26
references: 20089960
references: Ann Neurol. 1996 Dec;40(6):853-63
references: 9007090
references: N Engl J Med. 2006 Mar 2;354(9):899-910
references: 16510744
references: Curr Med Res Opin. 2007 Nov;23(11):2667-76
references: 17880754
references: Ann Neurol. 2001 Mar;49(3):290-7
references: 11261502
references: N Engl J Med. 2010 Feb 4;362(5):387-401
references: 20089952
references: Clin Immunol. 2012 Jan;142(1):49-56
references: 21367665
references: Med Sci Monit. 2001 Jan-Feb;7(1):93-8
references: 11208501
references: Lancet. 1998 Nov 7;352(9139):1498-504
references: 9820297
references: Clin Pharmacokinet. 1997 Feb;32(2):120-31
references: 9068927
references: Lancet Neurol. 2008 Oct;7(10):903-14
references: 18789766
references: Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12
references: 21067468
references: Neurology. 2000 Mar 14;54(5):1145-55
references: 10720289
references: N Engl J Med. 2000 Sep 28;343(13):898-904
references: 11006365
references: Lancet Neurol. 2009 Oct;8(10):889-97
references: 19729344